Exclusive: Eli Lilly memo says firm did not make false statements to FDA By Reuters
By Dan Levine and Marisa Taylor (Reuters) - A week before Eli Lilly (NYSE:LLY) disclosed to regulators that the U.S. Justice Department was investigating its New Jersey factory, the drugmaker told employees that its own inquiry, led by an outside law firm, found no evidence of wrongdoing there, according to a company memo reviewed by Reuters. On April 8, a group of employees filed an anonymous complaint internally alleging that an executive at its Branchburg, New Jersey, factory had altered documents required by the U.S. Food and Drug Administration. As Reuters reported last month, Lilly...
Continue reading